By Elin Aslanyan
Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA)
The workshop will be conducted by an international panel of experts in musculoskeletal imaging. The program is aimed at both rheumatologists and radiologists and will cover both introductory as well as advanced MRI.
According to a new French study in people with a family history of ankylosing spondylitis who carry the HLA-B27 gene, breastfeeding may provide a layer of protection against developing AS later in life.
According to a study presented at this year’s American College of Rheumatology Annual Meeting, excess weight loss can lead to improvements in psoriatic arthritis and psoriasis symptoms.
In September of this year the American College of Rheumatology released the first ever recommendations for physicians in the US for the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.